Not surprisingly, the effects of PCSK9 antibodies on triglyceride metabolism are more pronounced in patients with insulin-dependent type-2 diabetes and mixed hyperlipidemia, as shown in the ODYSSEY DM-INSULIN study [35]. Here, PCSK9 is linked to Combined hyperlipidemia.